Potential of Oxytocin in the Treatment of Schizophrenia

CNS Drugs
Paul D Shilling, David Feifel

Abstract

Schizophrenia is a heterogeneous, debilitating disorder characterized by three distinct sets of clinical features: positive symptoms, negative symptoms, and cognitive deficits. Extant antipsychotic drugs have been most successful at treating the positive symptoms of patients with schizophrenia but have minimal therapeutic effects on negative symptoms and cognitive deficits, which are the symptoms that best predict the poor prognosis of these patients. Therefore, there has been a major effort towards identifying compounds that alleviate these symptoms. Oxytocin (OT) is a nonapeptide that regulates peripheral reproductive-relevant functions, and also acts as a neurotransmitter in the brain. Converging evidence from both preclinical and clinical research suggests that OT may have therapeutic efficacy for the positive symptoms, negative symptoms, and cognitive deficits of schizophrenia. In the majority of the small, randomized, placebo-controlled clinical trials conducted to date, OT has shown particular promise in its potential to treat the intractable negative symptoms and social cognitive deficits exhibited by most of the patients with this debilitating disorder. In this leading article, we summarize the clinical evidence releva...Continue Reading

References

Jun 12, 1992·Annals of the New York Academy of Sciences·E TribolletS Jard
Jun 1, 1985·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·T TakagiK Yamaji
Jun 1, 1974·Canadian Psychiatric Association Journal·W Bujanow
Nov 4, 1972·British Medical Journal·W Bujanow
Apr 1, 1966·Obstetrical & Gynecological Survey·S R Sogolow
Jan 1, 1984·European Archives of Psychiatry and Neurological Sciences·P LinkowskiJ J Legros
Jan 15, 1997·Annals of the New York Academy of Sciences·T R InselZ Wang
Nov 14, 1997·International Clinical Psychopharmacology·D R Weinberger, B Gallhofer
Feb 10, 1999·Psychopharmacology·D Feifel, T Reza
Mar 29, 2001·Physiological Reviews·G Gimpl, F Fahrenholz
Oct 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·F ChampagneM J Meaney
Jun 3, 2005·Nature·Michael KosfeldErnst Fehr
Feb 17, 2006·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder
Oct 13, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ana B F EmilianoJulie L Fudge
Nov 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William T Carpenter, James I Koenig
Jan 30, 2008·Molecular Psychiatry·H K CaldwellW S Young
Jul 8, 2008·Journal of Neuroendocrinology·E Hrabovszky, Z Liposits
Jul 29, 2008·Progress in Brain Research·Alexa H Veenema, Inga D Neumann
Aug 2, 2008·Social Neuroscience·Szabolcs KériOguz Kelemen
Sep 3, 2008·European Journal of Clinical Pharmacology·Laura OttolenghiSilvio Garattini
Sep 6, 2008·Progress in Brain Research·Toshihide KurokiTatsuo Nakahara
Sep 17, 2008·Journal of Clinical Psychopharmacology·Menahem I KrakowskiKaren A Nolan
Nov 8, 2008·Science·Zoe R Donaldson, Larry J Young
Jul 28, 2009·Psychoneuroendocrinology·Gregor DomesSabine C Herpertz
Feb 5, 2010·The European Journal of Neuroscience·T A BaskervilleA J Douglas
Mar 4, 2010·The International Journal of Neuropsychopharmacology·Renan P SouzaJames L Kennedy
Mar 17, 2010·Endocrinology·Dara K ShahrokhMichael J Meaney
Mar 24, 2010·Schizophrenia Bulletin·Andrew J RosenfeldL Fredrik Jarskog
Apr 3, 2010·Biological Psychiatry·Ilanit GordonRuth Feldman
May 25, 2010·Physiology & Behavior·Jan G VeeningHenk P Barendregt
May 25, 2010·Current Opinion in Psychiatry·Maria Luisa Figueira, Sílvia Ouakinin
Jun 16, 2010·Schizophrenia Research·Renan P SouzaJames L Kennedy

❮ Previous
Next ❯

Citations

Mar 13, 2018·Current Opinion in Psychiatry·Mary V Seeman, Alexandre González-Rodríguez
Oct 26, 2018·Harvard Review of Psychiatry·Geneviève SauvéMartin Lepage
Jul 31, 2019·The Journal of Clinical Endocrinology and Metabolism·Mark Florian Joachim WeingartenAnke Tönjes
Sep 10, 2020·Frontiers in Psychiatry·Ann-Katrin KraeuterZoltán Sarnyai
Nov 20, 2019·Therapeutic Advances in Psychopharmacology·Cathy Davies, Sagnik Bhattacharyya
Apr 12, 2017·CNS Drugs·Joshua T Kantrowitz
Feb 9, 2019·European Archives of Psychiatry and Clinical Neuroscience·Jyothika KumarLena Palaniyappan
Jan 17, 2021·Communications Biology·Daniel MartinsYannis Paloyelis
Mar 16, 2021·Current Behavioral Neuroscience Reports·Marilyn HortaNatalie C Ebner
May 17, 2017·Neuroscience and Biobehavioral Reviews·Ellen R Bradley, Joshua D Woolley
Jul 16, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yasmine GomaaMark R Prausnitz
Jul 25, 2021·International Journal of Molecular Sciences·Cecilia RiccardiPaola Rocca
Jul 9, 2021·British Journal of Pharmacology·Ben HoughtonAlexis Bailey
Aug 17, 2021·Journal of Psychiatric Practice·Sara MedvedAlma MihaljeviĆ-Peleš
Jan 4, 2022·Cerebral Cortex·Marie ZeleninaDiana Prata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here